{"hands_on_practices": [{"introduction": "This practice challenges you to think like a biochemist in the lab. Separating molecules from a complex mixture is a fundamental task, and thin-layer chromatography (TLC) is a classic technique that beautifully illustrates how molecular properties govern behavior. By analyzing the structures of a triglyceride, a phospholipid, and cholesterol, you will predict their separation based on polarity and then use experimental data to confirm your hypothesis and calculate a key chromatographic parameter, the Retardation factor ($R_f$) [@problem_id:2300774].", "problem": "A biochemist is analyzing a lipid extract obtained from cultured animal cells. The extract is known to be a mixture of three primary lipids: triolein (a triglyceride), phosphatidylcholine (a phospholipid), and cholesterol (a steroid). To separate these components, the biochemist performs Thin-Layer Chromatography (TLC). The stationary phase is a silica gel plate ($\\text{SiO}_2 \\cdot n\\text{H}_2\\text{O}$), which is known to be highly polar. The mobile phase is a non-polar solvent mixture of hexane and ethyl acetate.\n\nThe initial mixture is spotted on a line designated as the origin. The solvent is then allowed to ascend the plate. After the run, the solvent front has traveled a total distance of 15.0 cm from the origin. Three distinct spots, labeled 1, 2, and 3, are visualized on the plate. The center of each spot is measured to be at the following distances from the origin:\n\n- Spot 1: 3.3 cm\n- Spot 2: 7.8 cm\n- Spot 3: 13.5 cm\n\nThe Retardation factor ($R_f$) for a compound is defined as the ratio of the distance traveled by the compound's spot to the distance traveled by the solvent front. Based on the fundamental principles of chromatography and the relative polarities of the three lipid types, which of the following options correctly identifies the molecule corresponding to each spot and provides the correct Retardation factor ($R_f$) for cholesterol?\n\nA. Spot 1: Phosphatidylcholine, Spot 2: Triolein, Spot 3: Cholesterol; $R_f$ for Cholesterol = 0.90\n\nB. Spot 1: Cholesterol, Spot 2: Phosphatidylcholine, Spot 3: Triolein; $R_f$ for Cholesterol = 0.22\n\nC. Spot 1: Triolein, Spot 2: Cholesterol, Spot 3: Phosphatidylcholine; $R_f$ for Cholesterol = 0.52\n\nD. Spot 1: Phosphatidylcholine, Spot 2: Cholesterol, Spot 3: Triolein; $R_f$ for Cholesterol = 0.52\n\nE. Spot 1: Cholesterol, Spot 2: Triolein, Spot 3: Phosphatidylcholine; $R_f$ for Cholesterol = 0.22", "solution": "In thin-layer chromatography on silica gel, the stationary phase is highly polar, so more polar analytes interact more strongly with the stationary phase and therefore travel shorter distances with a non-polar mobile phase. Conversely, less polar analytes interact weakly with the stationary phase and travel farther.\n\nAmong the given lipids, the relative polarity is: phosphatidylcholine (highly polar, zwitterionic headgroup) is most polar, cholesterol (one hydroxyl group with a largely hydrophobic sterol nucleus) is intermediate, and triolein (neutral triacylglycerol) is the least polar. Therefore, on silica with a non-polar solvent, the expected migration order from shortest to longest distance is phosphatidylcholine, then cholesterol, then triolein.\n\nThe Retardation factor ($R_f$) is defined by the chromatography principle:\n$$\nR_f = \\frac{d_{\\text{compound}}}{d_{\\text{solvent front}}}\n$$\nHere, the solvent front distance is $d_{\\text{solvent front}}=15.0$ cm. The measured compound distances from the origin are 3.3 cm, 7.8 cm, and 13.5 cm. Assigning identities by polarity and migration:\n- Spot 1 at 3.3 cm corresponds to phosphatidylcholine (most polar, shortest distance).\n- Spot 2 at 7.8 cm corresponds to cholesterol (intermediate).\n- Spot 3 at 13.5 cm corresponds to triolein (least polar, farthest distance).\n\nThe $R_f$ for cholesterol (Spot 2) is calculated as:\n$$\nR_f = \\frac{7.8}{15.0} = 0.52\n$$\nThis assignment and value correspond to option D.", "answer": "$$\\boxed{D}$$", "id": "2300774"}, {"introduction": "The primary role of fats in many organisms is to serve as a dense, long-term energy reserve. This exercise moves beyond the qualitative statement and into the quantitative details of bioenergetics, asking you to perform a complete ATP accounting for the breakdown of a fatty acid. By comparing the net energy yield from a saturated fatty acid (stearic acid) with a monounsaturated one (oleic acid), you will uncover how a single double bond impacts the metabolic pathway and the final energy tally [@problem_id:2300833].", "problem": "A biochemist is evaluating the energy yield from two common C18 fatty acids. The first is stearic acid (18:0), a fully saturated fatty acid. The second is oleic acid (18:1), a monounsaturated fatty acid with a single *cis*-double bond located between carbons 9 and 10 (counting from the carboxyl carbon). You are tasked with calculating the difference in the net Adenosine Triphosphate (ATP) yield from the complete aerobic oxidation of one molecule of each fatty acid.\n\nFor your calculations, use the following standard metabolic conversion values and rules:\n1.  The initial activation of any fatty acid in the cytosol requires an investment equivalent to 2 ATP molecules.\n2.  Each cycle of beta-oxidation that cleaves a two-carbon acetyl-CoA unit from a *saturated* portion of the acyl-CoA chain produces 1 $FADH_2$ and 1 $NADH$.\n3.  The complete oxidation of each resulting acetyl-CoA molecule through the citric acid cycle produces 3 $NADH$, 1 $FADH_2$, and 1 $GTP$ (which is energetically equivalent to 1 ATP).\n4.  The processing of the *cis*-double bond in oleic acid requires an isomerase enzyme. This allows beta-oxidation to proceed but bypasses the acyl-CoA dehydrogenase step for that particular cycle. As a result, 1 $FADH_2$ molecule is *not* generated during the cycle that processes the double bond.\n5.  In the electron transport chain, each molecule of $NADH$ generates 2.5 ATP, and each molecule of $FADH_2$ generates 1.5 ATP.\n\nCalculate the difference in total net ATP yield, defined as (Net ATP from stearic acid) - (Net ATP from oleic acid). Express your answer as a single number representing the difference in ATP molecules.", "solution": "Let $n$ be the number of carbons. For a saturated $n=18$ fatty acyl-CoA:\n- Number of acetyl-CoA produced: $n/2 = 9$.\n- Number of beta-oxidation cycles: $n/2 - 1 = 8$.\n\nGiven rules:\n- Activation cost: $-2$ ATP.\n- Each saturated beta-oxidation cycle yields 1 $FADH_2$ and 1 $NADH$.\n- Each acetyl-CoA oxidized in the citric acid cycle yields 3 $NADH$, 1 $FADH_2$, and 1 ATP (from GTP).\n- In the electron transport chain: each $NADH \\to 2.5$ ATP, each $FADH_2 \\to 1.5$ ATP.\n- For oleic acid (18:1 cis-9), the cycle that processes the double bond yields no $FADH_2$ but still yields $NADH$.\n\nStearic acid (18:0):\n- Beta-oxidation yields: 8 $FADH_2$ and 8 $NADH$.\n- Citric acid cycle from 9 acetyl-CoA: 27 $NADH$, 9 $FADH_2$, 9 ATP.\n- Totals: $NADH = 8 + 27 = 35$, $FADH_2 = 8 + 9 = 17$, ATP (substrate-level) $= 9$.\n- Convert to ATP and include activation:\n$$\\text{ATP}_{\\text{stearate}} = 35 \\times 2.5 + 17 \\times 1.5 + 9 - 2 = 87.5 + 25.5 + 9 - 2 = 120.$$\n\nOleic acid (18:1 cis-9):\n- Beta-oxidation cycles still 8, but one cycle skips acyl-CoA dehydrogenase, so $FADH_2$ production is reduced by 1 relative to saturated:\n  - Beta-oxidation yields: 7 $FADH_2$ and 8 $NADH$.\n- Citric acid cycle from 9 acetyl-CoA: 27 $NADH$, 9 $FADH_2$, 9 ATP (same as above).\n- Totals: $NADH = 8 + 27 = 35$, $FADH_2 = 7 + 9 = 16$, ATP (substrate-level) $= 9$.\n- Convert to ATP and include activation:\n$$\\text{ATP}_{\\text{oleate}} = 35 \\times 2.5 + 16 \\times 1.5 + 9 - 2 = 87.5 + 24 + 9 - 2 = 118.5.$$\n\nDifference requested:\n$$\\text{Difference} = \\text{ATP}_{\\text{stearate}} - \\text{ATP}_{\\text{oleate}} = 120 - 118.5 = 1.5.$$\n\nEquivalently, the difference arises solely from the single missing $FADH_2$ during processing of the double bond, giving $1 \\times 1.5 = 1.5$ ATP less for oleate.", "answer": "$$\\boxed{1.5}$$", "id": "2300833"}, {"introduction": "Lipids are not just for energy and membranes; they are also precursors to potent signaling molecules that regulate crucial physiological processes like inflammation. This problem places you in the role of a clinical researcher evaluating different anti-inflammatory drugs. You will need to apply your knowledge of the eicosanoid synthesis pathway, which begins with the release of arachidonic acid from membrane phospholipids, to predict the biochemical outcome of inhibiting the pathway at different key enzymatic steps [@problem_id:2300820].", "problem": "A patient is being treated for a severe chronic inflammatory condition with a high-dose regimen of a standard Non-Steroidal Anti-inflammatory Drug (NSAID), which functions as a non-selective Cyclooxygenase (COX) inhibitor. Despite the treatment, the patient's symptoms are only partially managed. Laboratory analysis of the patient's serum reveals that while levels of inflammatory prostaglandins are significantly suppressed, the levels of inflammatory leukotrienes are paradoxically elevated. As a next-line treatment, the physician considers prescribing an experimental drug that is a potent and highly selective inhibitor of cytosolic Phospholipase A2 (cPLA2).\n\nAssuming the new drug is administered and is effective, which of the following describes the most likely and direct biochemical outcome of switching from the COX inhibitor to the cPLA2 inhibitor?\n\nA. A further decrease in prostaglandin levels, accompanied by a significant further increase in leukotriene levels.\nB. A significant decrease in the levels of both prostaglandins and leukotrienes.\nC. A significant increase in prostaglandin levels, accompanied by a significant decrease in leukotriene levels.\nD. No change in prostaglandin or leukotriene levels, as the new drug targets a different class of enzymes.\nE. A decrease in the structural integrity of cell membranes, leading to widespread cell lysis.", "solution": "The eicosanoid biosynthesis pathway begins with the liberation of arachidonic acid (AA) from membrane phospholipids by cytosolic phospholipase A2 (cPLA$_2$). Symbolically,\n$$\n\\text{Membrane phospholipids} \\xrightarrow{cPLA_2} \\text{Arachidonic acid (AA)}.\n$$\nFree AA then serves as the common substrate for two major downstream branches:\n$$\n\\text{AA} \\xrightarrow{\\text{COX-1/2}} \\text{Prostaglandins and thromboxanes}, \\quad \\text{and} \\quad \\text{AA} \\xrightarrow{\\text{5-LOX}} \\text{Leukotrienes}.\n$$\n\nUnder a non-selective COX inhibitor (standard NSAID), the reaction $\\text{AA} \\xrightarrow{\\text{COX}} \\text{Prostaglandins}$ is inhibited, leading to a significant decrease in prostaglandins. Because AA continues to be generated by $cPLA_2$, the accumulated or unutilized AA can be diverted to the 5-lipoxygenase (5-LOX) pathway, causing a relative or absolute increase in leukotrienes. This explains the observed partial control of inflammation with suppressed prostaglandins and paradoxically elevated leukotrienes.\n\nSwitching to a potent and selective $cPLA_2$ inhibitor targets the upstream, rate-limiting liberation of AA itself. Inhibiting $cPLA_2$ reduces the availability of free AA, the common substrate for both COX and 5-LOX pathways. The direct biochemical consequence is a decrease in substrate supply to both branches:\n$$\n\\downarrow cPLA_2 \\;\\Rightarrow\\; \\downarrow \\text{AA} \\;\\Rightarrow\\; \\downarrow \\big(\\text{COX products: prostaglandins, thromboxanes}\\big) \\;\\text{and}\\; \\downarrow \\big(\\text{5-LOX products: leukotrienes}\\big).\n$$\n\nEvaluating the options based on this mechanism:\n- A is incorrect: although prostaglandins would further decrease, leukotrienes would not increase because their substrate (AA) is reduced.\n- B is correct: both prostaglandins and leukotrienes decrease due to reduced AA availability.\n- C is incorrect: prostaglandins would not increase because the upstream substrate is limited, even without COX inhibition.\n- D is incorrect: there will be a change, since $cPLA_2$ lies upstream of both branches.\n- E is incorrect: selective pharmacologic inhibition of $cPLA_2$ does not cause widespread membrane lysis; it prevents AA release from phospholipids.\n\nTherefore, the most likely and direct biochemical outcome of switching to a $cPLA_2$ inhibitor is a significant decrease in both prostaglandins and leukotrienes.", "answer": "$$\\boxed{B}$$", "id": "2300820"}]}